Crispr Therapeutics shares tumble after significant earnings miss
Bliss Kelly, President of U.S. Group Health at Teladoc Health, Inc. (NYSE:TDOC), a healthcare technology company with a market capitalization of $1.6 billion, recently executed a series of stock transactions, according to a recent SEC filing. The company, which InvestingPro analysis indicates is currently undervalued, maintains a GOOD financial health score despite recent market volatility. On March 3, Kelly sold 2,904 shares of Teladoc Health common stock at a price of $9.684 per share, amounting to a total transaction value of $28,122. This transaction comes amid a significant 15.7% decline in the stock price over the past week, though the shares have shown resilience with a 26.8% gain over the last six months.
In addition to the sale, Kelly also converted several restricted and performance stock units into common stock on February 28. These conversions included 1,404, 3,488, and 1,189 shares, respectively. These transactions did not involve any cash outlay, as the stock units were converted on a one-for-one basis into common stock. Following these transactions, Kelly’s direct ownership stands at 35,421 shares. For deeper insights into Teladoc’s valuation metrics and additional ProTips, subscribers can access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Teladoc Health Inc. reported its fourth-quarter 2024 earnings, revealing a revenue of $640.5 million, slightly above the forecast of $638.5 million. However, the company missed earnings per share (EPS) expectations, reporting -$0.28 compared to the anticipated -$0.23. The full-year revenue for 2024 was $2.6 billion, marking a 1% decline from 2023. Following these results, Stifel and Needham both maintained their Hold ratings on Teladoc shares, citing mixed outcomes and uncertainties regarding the company’s future performance. The analysts noted that Teladoc’s guidance for 2025 suggests flat to slight revenue growth, with expectations for improved performance weighted towards the second half of the year. The company is focusing on initiatives to stabilize its BetterHelp segment and expand its international operations. Despite the challenges, Teladoc ended the year with $1.3 billion in cash and cash equivalents, providing a cushion as it navigates through ongoing market pressures and strategic adjustments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.